1. 1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 71(3): 209-49. [DOI:10.3322/caac.21660]

2. Balazs K, Antal L, Safrany G, Lumniczky K (2021) Blood-derived biomarkers of diagnosis, prognosis and therapy response in prostate cancer patients. J Pers Med, 11(4): 296. [DOI:10.3390/jpm11040296]

3. Citrin DE (2017) Recent developments in radiotherapy. N Engl J Med, 377(11): 1065-75. [DOI:10.1056/NEJMra1608986]

4. Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, et al. (2007) Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol, 177(6): 2106-31. [DOI:10.1016/j.juro.2007.03.003]

5. Wallace TJ, Torre T, Grob M, Yu J, Avital I, Brücher BL, et al. (2014) Current approaches, challenges and future directions for monitoring treatment response in prostate cancer. J Cancer, 5(1): 3-9. [DOI:10.7150/jca.7709]

6. Araujo A, Cook LM, Frieling JS, Tan W, Copland JA, Kohli M, et al. (2021) Quantification and optimization of standard-of-care therapy to delay the emergence of resistant bone metastatic prostate cancer. Cancers (Basel), 13(4): 677. [DOI:10.3390/cancers13040677]

7. Tolkach Y and Kristiansen G (2018) The heterogeneity of prostate cancer: a practical approach. Pathobiology, 85(1-2): 108-16. [DOI:10.1159/000477852]

8. Yadav SS, Stockert JA, Hackert V, Yadav KK, Tewari AK (2018) Intratumor heterogeneity in prostate cancer. Urol Oncol, 36(8): 349-60. [DOI:10.1016/j.urolonc.2018.05.008]

9. Ku SY, Gleave ME, Beltran H (2019) Towards precision oncology in advanced prostate cancer. Nat Rev Urol, 16(11): 645-54. [DOI:10.1038/s41585-019-0237-8]

10. Labbé M, Hoey C, Ray J, Potiron V, Supiot S, Liu SK, et al. (2020) microRNAs identified in prostate cancer: Correlative studies on response to ionizing radiation. Mol Cancer, 19(1): 63. [DOI:10.1186/s12943-020-01186-6]

11. Dahariya S, Paddibhatla I, Kumar S, Raghuwanshi S, Pallepati A, Gutti RK (2019) Long non-coding RNA: classification, biogenesis and functions in blood cells. Mol Immunol, 112: 82-92. [DOI:10.1016/j.molimm.2019.04.011]

12. Kopp F and Mendell JT (2018) Functional classification and experimental dissection of long noncoding RNAs. Cell, 172(3): 393-407. [DOI:10.1016/j.cell.2018.01.011]

13. Schmitt AM and Chang HY (2016) Long noncoding RNAs in cancer pathways. Cancer Cell, 29(4): 452-63. [DOI:10.1016/j.ccell.2016.03.010]

14. Xie Y, Han J, Xie K, Gou Q (2022) LncRNAs as biomarkers for predicting radioresistance and survival in cancer: a meta-analysis. Sci Rep, 12(1): 18494. [DOI:10.1038/s41598-022-21785-1]

15. Shen X, Ding Y, Lu F, Yuan H, Luan W (2020) Long noncoding RNA MIR4435-2HG promotes hepatocellular carcinoma proliferation and metastasis through the miR-22-3p/YWHAZ axis. Am J Transl Res, 12(10): 6381-94. [DOI:10.3389/fonc.2020.00160]

16. Bai Y, Zhang G, Chu H, Li P, Li J (2019) The positive feedback loop of lncRNA DANCR/miR-138/Sox4 facilitates malignancy in non-small cell lung cancer. Am J Cancer Res, 9(2): 270-81.

17. Deng H, Zhu B, Dong Z, Jiang H, Zhao X, Wu S (2021) miR-214-5p targeted by lncRNA DANCR mediates TGF-β signaling pathway to accelerate proliferation, migration and inhibit apoptosis of prostate cancer cells. Am J Transl Res, 13(4): 2224-34.

18. Zhan Y, Chen Z, Li Y, He A, He S, Gong Y, et al. (2018) Long non-coding RNA DANCR promotes malignant phenotypes of bladder cancer cells by modulating the miR-149/MSI2 axis as a ceRNA. J Exp Clin Cancer Res, 37(1): 273. [DOI:10.1186/s13046-018-0921-1]

19. Chen C, Wang K, Wang Q, Wang X (2018) LncRNA HULC mediates radioresistance via autophagy in prostate cancer cells. Braz J Med Biol Res, 51(7): e7080. [DOI:10.1590/1414-431x20187080]

20. Zhao Y, Guo Q, Chen J, Hu J, Wang S, Sun Y (2014) Role of long non-coding RNA HULC in cell proliferation, apoptosis and tumor metastasis of gastric cancer: a clinical and in vitro investigation. Oncol Rep, 31(1): 358-64. [DOI:10.3892/or.2013.2850]

21. Mohammadi C, Khoei SG, Fayazi N, Mohammadi Y, Najafi R (2021) miRNA as promising theragnostic biomarkers for predicting radioresistance in cancer: A systematic review and meta-analysis. Crit Rev Oncol Hematol, 157: 103183. [DOI:10.1016/j.critrevonc.2020.103183]

22. Li Y, Liu R, Li J, Dong X, Shen J, Wu S (2019) Isoflurane promotes proliferation and invasion of cervical carcinoma cells via downregulation of miR-375 expression. Eur J Gynaecol Oncol, 40(3): 368-72.

23. Jalali S, Bhartiya D, Lalwani MK, Sivasubbu S, Scaria V (2013) Systematic transcriptome wide analysis of lncRNA-miRNA interactions. PLoS One, 8(2): e53823. [DOI:10.1371/journal.pone.0053823]

24. Chan MK, Chung JY, Tang PC, Chan AS, Ho JY, Lin TP, et al. (2022) TGF-β signaling networks in the tumor microenvironment. Cancer Lett, 550: 215925. [DOI:10.1016/j.canlet.2022.215925]

25. Cai CF, He Y, Yue D, Wang ZH, Guo N, Tian J (2023) DIRAS2 promotes radiation resistance in renal cell carcinoma via autophagy induction and MKK4-JNK1 pathway activation. Int J Radiat Res, 21(4): 805-13. [DOI:10.61186/ijrr.21.4.805]

26. Mirzaei S, Paskeh MD, Saghari Y, Zarrabi A, Hamblin MR, Entezari M, et al. (2022) Transforming growth factor-beta (TGF-β) in prostate cancer: A dual function mediator? Int J Biol Macromol, 206: 435-52. [DOI:10.1016/j.ijbiomac.2022.02.094]

27. Caja L, Dituri F, Mancarella S, Caballero-Diaz D, Moustakas A, Giannelli G, et al. (2018) TGF-β and the tissue microenvironment: Relevance in fibrosis and cancer. Int J Mol Sci, 19(5): 1294. [DOI:10.3390/ijms19051294]

28. Liu Q, Ma L, Jones T, Palomero L, Pujana MA, Martinez-Ruiz H, et al. (2018) Subjugation of TGFβ signaling by human papilloma virus in head and neck squamous cell carcinoma shifts DNA repair from homologous recombination to alternative end joining. Clin Cancer Res, 24(23): 6001-14. [DOI:10.1158/1078-0432.CCR-18-1346]

29. Nieto MA, Huang RY, Jackson RA, Thiery JP (2016) EMT: 2016. Cell, 166(1): 21-45. [DOI:10.1016/j.cell.2016.06.028]

30. Roach III M, Hanks G, Thames Jr H, Schellhammer P, Shipley WU, Sokol GH, et al. (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys, 65(4): 965-74. [DOI:10.1016/j.ijrobp.2006.04.029]

31. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 74(3): 229-63. [DOI:10.3322/caac.21834]

32. Macedo-Silva C, Miranda-Gonçalves V, Tavares NT, Barros-Silva D, Lencart J, Lobo J, et al. (2023) Epigenetic regulation of TP53 is involved in prostate cancer radioresistance and DNA damage response signaling. Signal Transduct Target Ther, 8(1): 395. [DOI:10.1038/s41392-023-01639-6]

33. Di Franco M, Mei R, Garcia C, Fanti S (2024) Treatment response assessment in mCRPC: is PSMA-PET/CT going to take the lead? Ther Adv Med Oncol, 16: 17588359241258367. [DOI:10.1177/17588359241258367]

34. Zakari S, Niels NK, Olagunju GV, Nnaji PC, Ogunniyi O, Tebamifor M, et al. (2024) Emerging biomarkers for non-invasive diagnosis and treatment of cancer: a systematic review. Front Oncol, 14: 1405267. [DOI:10.3389/fonc.2024.1405267]

35. Shi T, Gao G, Cao Y (2016) Long noncoding RNAs as novel biomarkers have a promising future in cancer diagnostics. Dis Markers, 2016: 9085195. [DOI:10.1155/2016/9085195]

36. Xing P, Wang Y, Zhang L, Ma C, Lu J (2021) Knockdown of lncRNA MIR4435-2HG and ST8SIA1 expression inhibits the proliferation, invasion and migration of prostate cancer cells in-vitro and in-vivo by blocking the activation of the FAK/AKT/β‑catenin signaling pathway. Int J Mol Med, 47(6): 1-13. [DOI:10.3892/ijmm.2021.4926]

37. Sun W, Zu S, Shao G, Wang W, Gong F (2021) Long non‐coding DANCR targets miR‐185‐5p to upregulate LIM and SH3 protein 1 promoting prostate cancer via the FAK/PI3K/AKT/GSK3β/snail pathway. J Gene Med, 23(7): e3344. [DOI:10.1002/jgm.3344]

38. Zheng P, Li H, Xu P, Wang X, Shi Z, Han Q, et al. (2018) High lncRNA HULC expression is associated with poor prognosis and promotes tumor progression by regulating epithelial-mesenchymal transition in prostate cancer. Arch Med Sci, 14(3): 679-86. [DOI:10.5114/aoms.2017.69147]

39. Ou ZL, Luo Z, Lu YB (2019) Long non-coding RNA HULC as a diagnostic and prognostic marker of pancreatic cancer. World J Gastroenterol, 25(46): 6728.

40. Pei L, Yan D, He Q, Kong J, Yang M, Ruan H, et al. (2023) LncRNA MIR4435-2HG drives cancer progression by modulating cell cycle regulators and mTOR signaling in stroma-enriched subtypes of urothelial carcinoma of the bladder. Cell Oncol (Dordr), 46(5): 1509-27. [DOI:10.1007/s13402-023-00826-5]

41. Yu X and Wang M (2022) LINC01204 negatively regulates the effect of miR-214 on lung cancer cell apoptosis, migration, invasion and radiosensitivity. Int J Radiat Res, 20(1): 15-20. [DOI:10.52547/ijrr.20.1.3]

42. Richardsen E, Andersen S, Al-Saad S, Rakaee M, Nordby Y, Pedersen MI, et al. (2019) Low expression of miR-424-3p is highly correlated with clinical failure in prostate cancer. Sci Rep, 9(1): 10662. [DOI:10.1038/s41598-019-47234-0]

43. Sun F, Wu KE, Yao Z, Mu X, Zheng Z, Sun M, et al. (2020) Long noncoding RNA LINC00963 induces NOP2 expression by sponging tumor suppressor miR-542-3p to promote metastasis in prostate cancer. Aging (Albany NY), 12(12): 11500. [DOI:10.18632/aging.103236]

44. Yin G, Yan C, Hao J, Zhang C, Wang P, Zhao C, et al. (2023) PRDM16, negatively regulated by miR-372-3p, suppresses cell proliferation and invasion in prostate cancer. Andrologia, 55(1): e9821829. [DOI:10.1155/2023/9821829]

45. Chen B, Dragomir MP, Yang C, Li Q, Horst D, Calin GA (2022) Targeting non-coding RNAs to overcome cancer therapy resistance. Signal Transduct Target Ther, 7(1): 121. [DOI:10.1038/s41392-022-00975-3]

46. Hu Z, Liu Y, Liu M, Zhang Y, Wang C (2023) Roles of TGF‑β signalling pathway-related lncRNAs in cancer. Oncol Lett, 25(3): 107. [DOI:10.3892/ol.2023.13693]

47. Zhang H, Meng H, Huang X, Tong W, Liang X, Li J, et al. (2019) lncRNA MIR4435-2HG promotes cancer cell migration and invasion in prostate carcinoma by upregulating TGF-β1. Oncol Lett, 18(4): 4016-21. [DOI:10.3892/ol.2019.10757]

48. Wu CT, Hsieh CC, Yen TC, Chen WC, Chen MF (2015) TGF-β1 mediates the radiation response of prostate cancer. J Mol Med (Berl), 93(1): 73-82. [DOI:10.1007/s00109-014-1206-6]

49. Reis ST, Pontes-Júnior J, Antunes AA, Sousa-Canavez JM, Abe DK, Cruz JA, et al. (2011) TGF-β1 expression as a biomarker of poor prognosis in prostate cancer. Clinics (Sao Paulo), 66: 1143-7. [DOI:10.1590/S1807-59322011000700004]

50. David M and Leslie S (2024) Prostate-specific antigen. StatPearls. Treasure Island (FL): StatPearls Publishing; 2024.

51. Gunnlaugsson A, Kjellén E, Bratt O, Ahlgren G, Johannesson V, Blom R, et al. (2020) PSA decay during salvage radiotherapy for prostate cancer as a predictor of disease outcome - 5 year follow-up of a prospective observational study. Clin Transl Radiat Oncol, 24: 23-28. [DOI:10.1016/j.ctro.2020.05.008]